Who Pays My Doctor?

Healthcare provider profile · identity verified

Douglas C Diruggiero, PAC

Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · CARTERSVILLE, GA · NPI 1730145327

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Douglas C Diruggiero, PAC received $366,354.35 in general payments during 2025 across 591 reported records.

Regeneron Healthcare Solutions, Inc. accounted for 22.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 30 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Otezla.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$366,354.35

591 reported records · 24 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $83,004.0622.7%1532025
Janssen Biotech, Inc. Unresolved — no canonical attribution shown $49,616.9913.5%632025
Lilly USA, LLC Unresolved — no canonical attribution shown $41,589.9311.3%572025
Arcutis Biotherapeutics, Inc. Unresolved — no canonical attribution shown $39,907.0610.9%662025
ABBVIE INC. Unresolved — no canonical attribution shown $30,565.418.3%452025
GENZYME CORPORATION Unresolved — no canonical attribution shown $30,169.998.2%342025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $18,526.115.1%92025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $15,857.874.3%432025
UCB, Inc. Unresolved — no canonical attribution shown $14,855.874.1%302025
Eli Lilly and Company Unresolved — no canonical attribution shown $14,623.974.0%132025
Amgen Inc. Unresolved — no canonical attribution shown $13,029.783.6%162025
Incyte Corporation Unresolved — no canonical attribution shown $3,827.861.0%42025
MAYNE PHARMA COMMERCIAL LLC Unresolved — no canonical attribution shown $3,300.000.9%22025
LEO Pharma Inc. Unresolved — no canonical attribution shown $2,224.230.6%112025
SUN PHARMACEUTICAL INDUSTRIES INC. Unresolved — no canonical attribution shown $2,051.790.6%202025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $1,975.000.5%12025
Kowa Pharmaceuticals America, Inc. Unresolved — no canonical attribution shown $450.000.1%12025
Galderma Laboratories, L.P. Unresolved — no canonical attribution shown $270.900.1%102025
Organon LLC Unresolved — no canonical attribution shown $257.810.1%52025
PFIZER INC. Unresolved — no canonical attribution shown $152.160.0%32025
Ortho Dermatologics, a division of Bausch Health US, LLC Unresolved — no canonical attribution shown $38.800.0%22025
SpringWorks Therapeutics, Inc. Unresolved — no canonical attribution shown $21.840.0%12025
LNHC, Inc Unresolved — no canonical attribution shown $19.150.0%12025
Fidia Pharma USA Inc. Unresolved — no canonical attribution shown $17.770.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$210,936.00119
Consulting Fee$89,667.3449
Travel and Lodging$51,306.11153
Food and Beverage$10,837.99261
Honoraria$3,300.002
Education$306.917

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. $102,824.93 177 2025
Source payment records
EBGLYSS
Normalized: ebglyss		 Drug Eli Lilly and Company, Lilly USA, LLC $51,255.00 62 2025
Source payment records
TREMFYA
Normalized: tremfya		 Drug Janssen Biotech, Inc. $42,357.07 50 2025
Source payment records
ZORYVE
Normalized: zoryve		 Drug Arcutis Biotherapeutics, Inc., Kowa Pharmaceuticals America, Inc. $40,357.06 67 2025
Source payment records
SKYRIZI
Normalized: skyrizi		 Biological ABBVIE INC. $30,512.07 42 2025
Source payment records
SPEVIGO
Normalized: spevigo		 Biological, Drug Boehringer Ingelheim Pharmaceuticals, Inc., LEO Pharma Inc. $18,541.64 10 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $14,855.87 30 2025
Source payment records
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $13,029.78 16 2025
Source payment records
Rhapsido
Normalized: rhapsido		 Drug Novartis Pharmaceuticals Corporation $8,513.26 19 2025
Source payment records
SIMPONI ARIA
Normalized: simponi aria		 Biological Janssen Biotech, Inc. $5,993.41 6 2025
Source payment records
OLUMIANT
Normalized: olumiant		 Drug Eli Lilly and Company $3,825.00 3 2025
Source payment records
ANZUPGO
Normalized: anzupgo		 Drug LEO Pharma Inc. $2,123.82 7 2025
Source payment records
ADBRY
Normalized: adbry		 Biological LEO Pharma Inc. $2,008.63 5 2025
Source payment records
Winlevi
Normalized: winlevi		 Drug SUN PHARMACEUTICAL INDUSTRIES INC. $1,522.68 2 2025
Source payment records
COSENTYX
Normalized: cosentyx		 Drug Novartis Pharmaceuticals Corporation $304.03 14 2025
Source payment records
NEMLUVIO
Normalized: nemluvio		 Drug Galderma Laboratories, L.P. $270.90 10 2025
Source payment records
VTAMA
Normalized: vtama		 Drug Organon LLC $196.52 2 2025
Source payment records
LITFULO
Normalized: litfulo		 Drug PFIZER INC. $152.16 3 2025
Source payment records
ILUMYA
Normalized: ilumya		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $143.45 12 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $53.34 3 2025
Source payment records
CIBINQO
Normalized: cibinqo		 Drug PFIZER INC. $48.91 2 2025
Source payment records
Leqselvi
Normalized: leqselvi		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $42.99 2 2025
Source payment records
JUBLIA
Normalized: jublia		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $38.80 2 2025
Source payment records
  • 2025-08-27 · Ortho Dermatologics, a division of Bausch Health US, LLC · $19.27 · Open Payments source
  • 2025-12-18 · Ortho Dermatologics, a division of Bausch Health US, LLC · $19.53 · Open Payments source
TALTZ
Normalized: taltz		 Drug Lilly USA, LLC $34.16 2 2025
Source payment records
LIBTAYO
Normalized: libtayo		 Biological Regeneron Healthcare Solutions, Inc. $27.17 1 2025
Source payment records
NEXPLANON
Normalized: nexplanon		 Drug Organon LLC $22.63 1 2025
Source payment records
GOMEKLI
Normalized: gomekli		 Drug SpringWorks Therapeutics, Inc. $21.84 1 2025
Source payment records
ZELSUVMI
Normalized: zelsuvmi		 Drug LNHC, Inc $19.15 1 2025
Source payment records
HYMOVIS
Normalized: hymovis		 Device Fidia Pharma USA Inc. $17.77 1 2025
Source payment records
TRILURON
Normalized: triluron		 Device Fidia Pharma USA Inc. $17.77 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
OTEZLA
otezla		 2025 Otezla 2024 11
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Amgen Inc.
Exact reporting entity; no affiliate inference		 2025 OTEZLA
open payments reported associated product		 CMS Open Payments — General Payments
177267 supporting records · 48600 recipient NPIs · example record 1226871616 		Otezla · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
KetoconazoleKetoconazole179108
Triamcinolone AcetonideTriamcinolone Acetonide170145
Clobetasol PropionateClobetasol Propionate7654
MupirocinMupirocin6653
Dupixent PenDupilumab50suppressed
Minocycline HclMinocycline Hcl3928
FluorouracilFluorouracil3531
MinoxidilMinoxidil35suppressed
MetronidazoleMetronidazole3425
CiclopiroxCiclopirox Olamine2922
Clindamycin PhosphateClindamycin Phosphate2320
CiclopiroxCiclopirox2216
HydrocortisoneHydrocortisone1816
Mometasone FuroateMometasone Furoate1714
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim1616
Cosentyx Unoready PenSecukinumab15suppressed
ImiquimodImiquimod15suppressed
Terbinafine HclTerbinafine Hcl14suppressed
ValacyclovirValacyclovir Hcl1411
Betamethasone DipropionateBetamethasone Dipropionate12suppressed
Bimzelx AutoinjectorBimekizumab-Bkzx12suppressed
Cosentyx Sensoready PenSecukinumab12suppressed
TacrolimusTacrolimus1211
OtezlaApremilast11suppressed
PrednisonePrednisone11suppressed
Taltz AutoinjectorIxekizumab11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $366,354.35 · 591 records Regeneron Healthcare Solutions, Inc. ADBRY, ANZUPGO, Bimzelx, CIBINQO, COSENTYX, DUPIXENT, EBGLYSS, GOMEKLI, HYMOVIS, ILUMYA, JUBLIA, LIBTAYO, LITFULO, Leqselvi, NEMLUVIO, NEXPLANON, OLUMIANT, OTEZLA, RINVOQ, Rhapsido, SIMPONI ARIA, SKYRIZI, SPEVIGO, TALTZ, TREMFYA, TRILURON, VTAMA, Winlevi, ZELSUVMI, ZORYVE 1 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error